<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>N-(2-Hydroxypropyl)<z:chebi fb="0" ids="51759">methacrylamide</z:chebi> (<z:chebi fb="0" ids="53440">HPMA</z:chebi>)-lectin (wheat germ agglutinin (WGA), peanut agglutinin (<z:chebi fb="3" ids="48021">PNA</z:chebi>)) drug conjugates for treatment of the pre-cancerous conditions <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> are being developed </plain></SENT>
<SENT sid="1" pm="."><plain>Cell-surface <z:chebi fb="0" ids="17089">glycoproteins</z:chebi> that are altered in disease and development bind lectins </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="3" ids="48021">PNA</z:chebi> binds <z:chebi fb="0" ids="36219">alpha-lactose</z:chebi> and the <z:e sem="disease" ids="C1406916" disease_type="Disease or Syndrome" abbrv="">Thomsen</z:e>-Friedenreich (TF) antigen, a disease- and development-associated <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="3" ids="48021">PNA</z:chebi> incorporation in conjugates may allow for preferential delivery to diseased over healthy tissues </plain></SENT>
<SENT sid="4" pm="."><plain>Conjugates were prepared by attaching lectins to <z:chebi fb="0" ids="53440">HPMA</z:chebi> <z:chebi fb="5" ids="53310">copolymers</z:chebi> via an <z:chebi fb="0" ids="29337,32988">amide</z:chebi> linkage </plain></SENT>
<SENT sid="5" pm="."><plain>Frontal affinity chromatography was used to measure dissociation constants (K(d)) of free and conjugated lectins </plain></SENT>
<SENT sid="6" pm="."><plain>Animal models of <z:hpo ids='HP_0002583'>colitis</z:hpo> (DSS, <z:chebi fb="0" ids="53063,53506">TNBS</z:chebi>/<z:chebi fb="0" ids="16236">EtOH</z:chebi>) were developed </plain></SENT>
<SENT sid="7" pm="."><plain>Human biopsy specimens were obtained </plain></SENT>
<SENT sid="8" pm="."><plain>Free and <z:chebi fb="0" ids="53440">HPMA</z:chebi> <z:chebi fb="5" ids="53310">copolymer</z:chebi>-conjugated <z:chebi fb="0" ids="37926">FITC</z:chebi>-labeled lectin and anti-TF antigen antibody binding patterns were examined in <z:mpath ids='MPATH_458'>normal</z:mpath> neonatal, adult and diseased rodent tissues and <z:mpath ids='MPATH_458'>normal</z:mpath> and diseased human tissues </plain></SENT>
<SENT sid="9" pm="."><plain>K(d) values of free and conjugated lectins were similar ( approximately 10(-5) M(-1)) </plain></SENT>
<SENT sid="10" pm="."><plain>Free and conjugated lectins had comparable binding patterns </plain></SENT>
<SENT sid="11" pm="."><plain>In health, strong WGA binding was seen in goblet cells; <z:chebi fb="3" ids="48021">PNA</z:chebi> binding was minimal, occurring only in the supranuclear goblet cell region </plain></SENT>
<SENT sid="12" pm="."><plain>In disease, WGA binding was not altered, but <z:chebi fb="3" ids="48021">PNA</z:chebi> binding was increased in both human and rodent tissues; entire goblets bound the lectin </plain></SENT>
<SENT sid="13" pm="."><plain>Anti-TF antigen antibody binding was minimal, but did overlap with <z:chebi fb="3" ids="48021">PNA</z:chebi> binding patterns both in <z:mpath ids='MPATH_458'>normal</z:mpath> and diseased tissues </plain></SENT>
<SENT sid="14" pm="."><plain>Conjugation of lectins to <z:chebi fb="0" ids="53440">HPMA</z:chebi> <z:chebi fb="5" ids="53310">copolymers</z:chebi> does not affect binding affinity </plain></SENT>
<SENT sid="15" pm="."><plain>Alterations in <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> structures in development and disease resulted in modified lectin binding patterns </plain></SENT>
<SENT sid="16" pm="."><plain>In development and disease, the <z:chebi fb="3" ids="48021">PNA</z:chebi> binding seen was to the TF antigen and other <z:chebi fb="8" ids="17716">lactose</z:chebi>-containing <z:chebi fb="0" ids="17089">glycoproteins</z:chebi> </plain></SENT>
<SENT sid="17" pm="."><plain>The results suggest that site-specific delivery of therapeutic agents such as <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CsA) for <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> and mesochlorin e(6) for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> may be achieved </plain></SENT>
<SENT sid="18" pm="."><plain>P(<z:chebi fb="0" ids="53440">HPMA</z:chebi>)-lectin-CsA conjugates have been prepared and preliminary in vivo studies are underway </plain></SENT>
</text></document>